Abstract
The cardiovascular system exhibits significant daily rhythms in physiologic processes (heart rate, blood pressure, cardiac contractility and function), and molecular gene and protein expression. An increasing number of clinical and experimental studies demonstrate the circadian system is an important underlying mechanism that coordinates these rhythmic processes for the health of the cardiovascular system. However, what happens when rhythms are disturbed has been generally clinically unappreciated. Here we describe the profound adverse impact of disturbed circadian rhythms and sleep on the cardiovascular system, including recovery from myocardial infarction in acute care settings, shift work and heart disease, sleep disorders including obstructive sleep apnea, and cardiovascular pathophysiology associated with disturbed nocturnal blood pressure profiles. We also discuss therapeutic applications of circadian rhythms for the cardiovascular system. Cardiovascular disease is a leading cause of death worldwide, and applying circadian biology to cardiology (and indeed medicine in general) provides a new translational approach to benefit patients clinically.
Keywords: Cardiovascular, chronotherapy, circadian, intensive care, obstructive sleep apnea, shift work, sleep.
Current Pharmaceutical Design
Title:Disruption of Circadian Rhythms and Sleep on Critical Illness and the Impact on Cardiovascular Events
Volume: 21 Issue: 24
Author(s): Cristine J. Reitz and Tami A. Martino
Affiliation:
Keywords: Cardiovascular, chronotherapy, circadian, intensive care, obstructive sleep apnea, shift work, sleep.
Abstract: The cardiovascular system exhibits significant daily rhythms in physiologic processes (heart rate, blood pressure, cardiac contractility and function), and molecular gene and protein expression. An increasing number of clinical and experimental studies demonstrate the circadian system is an important underlying mechanism that coordinates these rhythmic processes for the health of the cardiovascular system. However, what happens when rhythms are disturbed has been generally clinically unappreciated. Here we describe the profound adverse impact of disturbed circadian rhythms and sleep on the cardiovascular system, including recovery from myocardial infarction in acute care settings, shift work and heart disease, sleep disorders including obstructive sleep apnea, and cardiovascular pathophysiology associated with disturbed nocturnal blood pressure profiles. We also discuss therapeutic applications of circadian rhythms for the cardiovascular system. Cardiovascular disease is a leading cause of death worldwide, and applying circadian biology to cardiology (and indeed medicine in general) provides a new translational approach to benefit patients clinically.
Export Options
About this article
Cite this article as:
Reitz J. Cristine and Martino A. Tami, Disruption of Circadian Rhythms and Sleep on Critical Illness and the Impact on Cardiovascular Events, Current Pharmaceutical Design 2015; 21 (24) . https://dx.doi.org/10.2174/1381612821666150706105926
DOI https://dx.doi.org/10.2174/1381612821666150706105926 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial (Thematic Issue: Advances in The Therapy of Atrial Fibrillation: Incrementally Progressive But Not Without Missteps)
Current Cardiology Reviews Statins and Carotid Intima-Media Thickness Reduction: An Up-to-Date Review
Current Medicinal Chemistry Modulators of Vascular Sex Hormone Receptors and their Effects in Estrogen-Deficiency States Associated with Menopause
Recent Patents on Cardiovascular Drug Discovery Atrial Tachycardias Following Atrial Fibrillation Ablation
Current Cardiology Reviews Asthma-COPD Overlap: A more Simplistic Approach
Current Respiratory Medicine Reviews Clinical Trials: How to Assess Confounding and Why So
Current Clinical Pharmacology Immunocal® and Preservation of Glutathione as a Novel Neuroprotective Strategy for Degenerative Disorders of the Nervous System
Recent Patents on CNS Drug Discovery (Discontinued) Intravenous Thrombolysis with rt-PA in Acute Stroke Patients Aged ≥80 Years
Letters in Drug Design & Discovery Actions of Adjunctive Nutritional Antioxidants in Periodontitis and Prevalent Systemic Inflammatory Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets Diagnosis of Vulnerable Plaque and Vulnerable Patient by Coronary Angioscopy and Multi-detector Row Computed Tomography (MDCT) — From Invasive to Non-invasive Plaque Imaging
Vascular Disease Prevention (Discontinued) Histone Methylation and Transcriptional Regulation in Cardiovascular Disease
Cardiovascular & Hematological Disorders-Drug Targets The Impact of Metabolic Disease Associated with Metabolic Syndrome on Human Pregnancy
Current Pharmaceutical Biotechnology Monocyte Cyclooxygenase-2 Activity: A New Therapeutic Target for Atherosclerosis?
Current Drug Targets - Cardiovascular & Hematological Disorders Disorders of Innate Immunity in Human ageing and effects of Nutraceutical Administration
Endocrine, Metabolic & Immune Disorders - Drug Targets Ethnic and Geographical Differences in Ischaemic Stroke Among Young Adults
Current Vascular Pharmacology Physical Exercise and ACE2-Angiotensin-(1-7)-Mas Receptor Axis of the Renin Angiotensin System
Protein & Peptide Letters Neuroprotective Therapies for Alzheimers Disease
Current Pharmaceutical Design Prophylactic Potential of Conventional and Supercritical Garlic Extracts to Alleviate Diet Related Malfunctions
Recent Patents on Food, Nutrition & Agriculture Signs and Related Mechanisms of Ethanol Hepatotoxicity
Current Drug Abuse Reviews A Review of IGF1 Signaling and IGF1-related Long Noncoding RNAs in Chemoresistance of Cancer
Current Cancer Drug Targets